Related Experiment Video

Updated: Jul 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Potent oncolytic activity of human enteroviruses against human prostate cancer

Linda J Berry1, Gough G Au, Richard D Barry

  • 1The Picornavirus Research Unit, School of Biomedical Sciences, Faculty of Health, The University of Newcastle, Newcastle, New South Wales, Australia.

The Prostate
|February 22, 2008
PubMed
Abstract

Insights

Enteroviruses Coxsackievirus A21 (CVA21), CVA21-DAFv, and Echovirus 1 (EV1) show promise as oncolytic agents for prostate cancer. These viruses effectively target and reduce tumor burdens in preclinical models.

Area of Science:

  • Oncolytic virotherapy
  • Virology
  • Cancer research

Background:

  • Oncolytic virotherapy presents a novel treatment for prostate cancer, particularly for therapy-resistant stages.
  • Enteroviruses offer targeted tumor cell destruction, sparing healthy tissues.
  • Coxsackievirus A21 (CVA21), a variant (CVA21-DAFv), and Echovirus 1 (EV1) are investigated as potential oncolytic agents.

Purpose of the Study:

  • To evaluate the efficacy of CVA21, CVA21-DAFv, and EV1 as oncolytic agents against human prostate cancer.
  • To assess the expression of viral receptors on prostate cancer cells.
  • To determine the in vitro and in vivo oncolytic potential of these enteroviruses.

Main Methods:

  • Flow cytometry was used to assess viral receptor expression (ICAM-1, DAF, integrin alpha(2)beta(1)) on prostate cancer cell lines.
  • In vitro cell lysis assays were performed to determine susceptibility to viral oncolysis.
  • In vivo efficacy was evaluated using xenograft models in SCID mice with systemic viral challenge.

Main Results:

  • Most prostate cancer lines expressed ICAM-1, DAF, or alpha(2)beta(1), enabling significant in vitro oncolysis.
  • Systemic administration of all three viruses reduced tumor burdens in vivo.
  • A dose-dependent therapeutic response was observed for EV1 in the LNCaP xenograft model.

Conclusions:

  • Enteroviruses CVA21, CVA21-DAFv, and EV1 demonstrate potential as potent oncolytic agents for human prostate cancer.
  • These viruses effectively target prostate cancer cells, offering a promising therapeutic avenue.

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...